Kevin M. Crowley was named vice president of medicalproducts at Epitope Inc. of Beaverton, Ore. He was vicepresident of sales and marketing at Pharmacia Diagnostics Inc.Epitope (ASE:EPT) is developing diagnostic tests for AIDS andother indications, therapeutic anti-protozoal drugs and, throughits agricultural subsidiary, Agritope Inc., new plant varieties.
Genelabs Technologies Inc. named John Hegedus senior vicepresident of corporate development. He was previously vicepresident of corporate licensing at Sterling Drug Inc. Genelabs(NASDAQ:GNLB) of Redwood City, Calif., is focused on thedevelopment and commercialization of products for thediagnosis and treatment of viral diseases and cancer.
Cygnus Therapeutic Systems of Redwood City, Calif., namedBruce Bennett vice president of manufacturing and operations.He previously held manufacturing positions at Hanson plc andIntermedics Inc. Cygnus (NASDAQ:CYGN) develops transdermaldrug delivery systems.
Matrix Pharmaceuticals Inc. of Menlo Park, Calif., named JeanHuxsoll vice president of operations. She was formerly seniordirector of manufacturing at Applied Immune Sciences. Matrix(NASDAQ:MATX) is using its patented protein matrixtechnology to develop products to improve the effectivenessand reduce the systemic toxicity of establishedchemotherapeutic agents.
Cel-Sci Corp. of Alexandria, Va., named Michael Chirigos to itsscientific advisory board. He was the deputy chief of science atthe U.S. Army Medical Research Institute of Infectious Diseases.Cel-Sci (NASDAQ:CELI) is a pioneer of combination therapyusing lymphokine and cytokine mixtures for the treatment ofcancers and immunodeficiencies.
John Chappell, former chairman of SmithKline Beecham, joinedthe board of directors of Triplex Pharmaceutical Corp. of TheWoodlands, Texas. The privately held company is developingnovel human therapeutics based on triple-helix technology.
Attorney and biochemist Albert Halluin has joined thepartnership of Limbach & Limbach in San Francisco. He isformer vice president and chief counsel for Cetus Corp.
John Patrick Munson, president of Syntex PharmaceuticalsInternational, has been named to the board of T Cell SciencesInc. The Cambridge, Mass., company (NASDAQ:TCEL) is using Tcell and soluble receptor technology to develop pharmaceuticalproducts to treat diseases of inflammation, autoimmunity andcancer.
(c) 1997 American Health Consultants. All rights reserved.